Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHRH1SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC6A2
The experimentally established mechanism targets of Orphenadrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 1.00 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 1.00 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.73 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.73 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.73 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL119471 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL29359844 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL1235378 | 0.98 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL30903909 | 0.98 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL4338150 | 0.97 | SLC6A2 (0.94) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL29519368 | 0.90 | LMNA (0.84) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL2615259 | 0.88 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL637495 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL4667597 | 0.87 | CYP2D6 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL15529408 | 0.87 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8390 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| WO-1996008229-A2 | MATRIX FOR TRANSDERMAL DRUG DELIVERY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-03-21 | — | — | WO | claimed |
| US-5407834-A | Monoclonal antibody which binds phencyclidine and metabolites, raised against specified immunogen, lacking specifed cross reactivity | ABBOTT LABORATORIES (US) | 1995-04-18 | — | — | US | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| WO-1994003166-A1 | IBUPROFEN-MUSCLE RELAXANT COMBINATIONS | MERCK & CO., INC. (US) | 1994-02-17 | — | — | WO | claimed |
| EP-0367746-B1 | Sustained release drug-resin complexes | RICHARDSON VICKS INC (US) | 1994-02-02 | — | — | EP | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| US-4780463-A | CONTAINING PROPIONIC ACID COMPOUNDS | ANALGESIC ASSOCIATES (US) | 1988-10-25 | — | — | US | claimed |
| US-4551473-A | Method of inhibiting snoring and obstructive sleep apnea | SCHOSSOW GEORGE W | 1985-11-05 | — | — | US | claimed |